During the past decade, Hematology/Oncology Clinic conducted 63 clinical trials. In the 10-year time frame, 63 clinical trials started and 57 clinical trials were completed, i.e. on average, 90.5% percent of trials that started reached the finish line to date. In the past 5 years, 39 clinical trials started and 26 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hematology/Oncology Clinic" #1 sponsor was "National Cancer Institute (NCI)" with 31 trials, followed by "SWOG Cancer Research Network" with 22 trials sponsored, "SCRI Development Innovations, LLC" with 10 trials sponsored, "Eli Lilly and Company" with 5 trials sponsored and "Genentech, Inc." with 5 trials sponsored. Other sponsors include 46 different institutions and companies that sponsored additional 39 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hematology/Oncology Clinic" #1 collaborator was "National Cancer Institute (NCI)" with 35 trials as a collaborator, "NRG Oncology" with 8 trials as a collaborator, "Bayer" with 3 trials as a collaborator, "Canadian Cancer Trials Group" with 3 trials as a collaborator and "Eli Lilly and Company" with 3 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "Hematology/Oncology Clinic" are "Recurrent Squamous Cell Lung Carcinoma" (10 trials), "Breast Cancer" (8 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials), "Multiple Myeloma" (7 trials) and "Chronic Lymphocytic Leukemia" (6 trials). Many other conditions were trialed in "Hematology/Oncology Clinic" in a lesser frequency.

Most popular intervention types in "Hematology/Oncology Clinic" are "Drug" (108 trials), "Other" (51 trials), "Biological" (33 trials), "Procedure" (19 trials) and "Radiation" (5 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (33 trials), "Quality-of-Life Assessment" (17 trials), "Paclitaxel" (16 trials), "Carboplatin" (14 trials) and "Bevacizumab" (13 trials). Other intervention names were less common.

The vast majority of trials in "Hematology/Oncology Clinic" are 96 trials for "All" genders, 20 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "Hematology/Oncology Clinic". undefined are not yet recruiting, 34 are recruiting, 36 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 42 completed trials in Hematology/Oncology Clinic, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Hematology/Oncology Clinic, 7 "Phase 1" clinical trials were conducted, 54 "Phase 2" clinical trials and 68 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".